Joan Elise Dubinsky
Independent Ethics Advisor to Boards and Governance Officials, Lecturer in Ethics in Public Administration and International Organizations, Former Chief Ethics Officer, United Nations
Joan Elise Dubinsky has been globally responsible for Ethics and Compliance functions in complex multinational corporations and international organizations and consulted with organizations around the world in integrating values, virtues, and ethics into their culture and operations. Ms. Dubinsky is currently a University Lecturer and Organizational Consultant affiliated with the School of Public Policy at the University of Maryland, the Heller School of Social Policy and Management, Brandeis University, the Center for Professional Responsibility in Business and Society at the University of Illinois, and the Rutland Institute of Ethics, Clemson, University. She is a frequent lecturer in business ethics, international affairs, social policy, and management. Ms. Dubinsky’s research examines the nature of independence in business and organizational life, the influence of corporate culture on workplace and marketplace behavior, and the nature of conflicts of interest.
Ms. Dubinsky previously served as an Independent Ethics Advisor to the Board of Directors of the The Global Fund to Fight AIDS, Tuberculosis and Malaria where she provided independent and objective guidance on addressing institutional and individual ethical risks facing the Global Fund, including high-stakes internal investigations, challenges to executive and governance search processes, and maintaining balance between management and governance mandates. Prior to this Ms. Dubinsky was the Chief Ethics Officer/Director of Ethics at the United Nations reporting to the Secretary-General of the UN and accountable for ensuring that over 45,000 UN staff globally supported and upheld the Organization’s primary ethical values of integrity, accountability, and transparency.
Ms. Dubinsky’s specialties include third party/supply chain due diligence for anti-corruption compliance program effectiveness, ethical leadership development and evaluation, program evaluation and ethics risk assessments, and confidential investigations into allegations of misconduct or corporate wrongdoing.